Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPISTRY phase II platform trial
2020-001847-16Phase 2Active
- Sponsor
- Roche
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of atezolizumab, entrectinib, ipatasertib, inavolisib, alectinib and 4 more in Nonhematologic neoplasms, central nervous system tumor and neuroblastoma (9 cohorts), sponsored by Roche. Primary endpoint: Objective response rate. Started Nov 2020; status: active.
02
Drugs
atezolizumabentrectinibipatasertibinavolisibalectinib
03
Conditions
Nonhematologic neoplasmscentral nervous system tumorneuroblastoma
Beyond the preview
Go deeper on 2020-001847-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001847-16.